Form 4: Day One Biopharmaceuticals Executive Adam Dubow Reports Stock Transactions
SEC Form 4 Filing
Adam Dubow, General Counsel of Day One Biopharmaceuticals, reports the acquisition and disposal of common stock and Restricted Stock Units (RSUs) related to tax liability coverage.
Summary
- On May 15, 2025, Adam Dubow, General Counsel of Day One Biopharmaceuticals, engaged in multiple transactions involving the company's common stock and Restricted Stock Units (RSUs).
- These transactions included the acquisition of common stock through the vesting of RSUs and the subsequent sale of shares to cover tax liabilities.
- Specifically, 4,552 shares were sold at a weighted average price of $6.2579 per share, with prices ranging from $6.19 to $6.32.
- The reported transactions resulted in a net decrease in the number of shares held directly by Dubow.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions related to compensation and tax obligations, without indicating any strategic shift or concern.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment between management's actions and company performance. These filings are crucial for maintaining market integrity and investor confidence.
Comparison to Industry Standards
- Tracking insider transactions is a common practice in the pharmaceutical industry.
- Similar filings are routinely made by executives at companies like Pfizer, Amgen, and Johnson & Johnson.
- The volume and frequency of these transactions are typical for executives receiving stock-based compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders as they are related to executive compensation and tax obligations.
- Transparency through this filing helps maintain investor confidence.
Key Dates
| Date | Description |
|---|---|
| 05/15/2025 | Date of earliest transaction: Acquisition of common stock through RSU vesting. |
| 05/15/2025 | RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments thereafter on February 15, May 15, August 15 and November 15. |
| 05/16/2025 | Sale of shares to cover tax liability. |
| 05/19/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Day One Biopharmaceuticals, DAWN, Adam Dubow, Restricted Stock Units, RSU, Common Stock, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.